Industry Outlook
The travel vaccines market is set to reach US$ 6,886.7 Mn by 2026 from US$ 3,592.1 Mn in 2017 showcasing steady growth at a compounded annual growth rate (CAGR) of 7.5% during the forecast period from 2018 to 2026. As per the research findings of World Tourism Organization (WTO) the number of international arrivals throughout the globe is expected to reach 1.6 billion by 2020. It is estimated that 51% of these travelers accounted for holiday and recreational purpose, 15% tourist traveled for business purpose and 24% reported travel for religious reason and pilgrimage.
Travelers are at a high risk to bacterial and viral infection due to sudden change in humidity, altitude, temperature, poor hygiene and lack of medical services in remote areas etc. The World Health Organization (WHO) has drafted a treatment guideline for the travelers primarily focusing on the importance of vaccination as a preventive measure classified as routine, recommended and required vaccination.
Market Synopsis
Required vaccination are gaining prominence due to sudden outbreak of fatal diseases such as ebola, zika and middle east respiratory syndrome
Routine vaccination holds the largest market share by type in the travel vaccines market. It is helpful in developing immunity in humans against infectious diseases such as influenza, MMR, tuberculosis and diphtheria etc. The other factors responsible for the dominance of routine vaccination are the rising prevalence of infectious diseases and proactive government policies to promote vaccination in all age groups. Favorable reimbursement scenario has a positive impact on the routine vaccination market growth. Recommended vaccination are gaining popularity on account of facts such as increasing number of visitors globally. They are taken two months in advance on physicians recommendation to build immunity against endemic diseases such as cholera, diarrhea, Japanese encephalitis etc. Required vaccination will be the fastest growing segment on account of factors such as sudden outbreak of fatal diseases such as ebola, zika, malaria and middle east respiratory syndrome.
Increasing public health awareness and well-developed healthcare infrastructure to drive North America market growth
North America is the clear leader in travel vaccines market. The key parameters which propel the travel vaccines market growth in North America are increasing public health awareness and existence of well-developed healthcare infrastructure. Presence of key players and implementation of treatment guidelines emphasizing preventive care in citizens travelling abroad drive the North America market. European medical agency has made it mandatory for visitors to get vaccinated at the port of entry for infectious diseases such as tuberculosis, swine flu and hepatitis B etc. Asia Pacific will be showcasing fastest growth during the forecast period owing to rising prevalence of infectious diseases and rampant growth in tourism sector. Middle East and Africa performs stringent vaccination of the haj piligrims in order to prevent the spread of middle east respiratory syndrome (MERS). Since the outbreak of fatal diseases such as ebola and zika the healthcare agencies in Latin America and African region the government healthcare bodies have invested huge funds in developing vaccines to protect the health of their citizens.
Historical & Forecast Period
2016 – Historical Year
2017 – Base Year
2018-2026 – Forecast Period
This research report presents the analysis of each segment from 2016 to 2026 considering 2017 as the base year for the research. Compounded annual growth rate (CAGR) for each respective segments are calculated for the forecast period from 2018 to 2026.
Report Scope by Segments
Organic and inorganic market growth analysis were employed to determine the market estimation and compounded annual growth rate. The travel vaccines market segmentation comprises of by type and by geography.
By Type (2016–2026; US$ Mn)
Geography Segment (2016–2026; US$ Mn)
Market assessment is performed in the scope of report to understand the latest market trends prevailing in the travel vaccines market. Comprehensive study was performed to understand the disease etiology of different infections encountered by travelers throughout the globe and the preventive action taken by the global healthcare agencies. Competitive landscape is covered in the scope of the report to understand the competition existing among key players. The vaccines classified as routine, recommended and required vaccination are covered under the product portfolio segment. Major players providing travel vaccines are Baxter AG, Bharat Biotech, GlaxoSmithkline, Plc., Inovio Pharmaceuticals, Inc., Merck & Co., Inc., Novartis AG, PaxVax Corporation, Sanofi Pasteur SA, Valneva SE and VBI Vaccines, Inc.
Key questions answered in this report
Chapter 1. Preface
1.1. Report Scope and Description
1.1.1. Purpose of the Report
1.1.2. Target Audience
1.1.3. USP and Key Offerings
1.2. Research Scope
1.3. Research Methodology
1.3.1. Phase I-Secondary Research
1.3.2. Phase II-Primary Research
1.3.3. Approach Adopted
1.3.4. Top-down Approach
1.3.5. Bottom-up Approach
1.3.6. Phase III-Expert Panel Review
1.3.7. Assumptions
1.4. Market Segmentation
Chapter 2. Executive Summary
2.1. Global Travelers Vaccine Market Portraiture
2.2. Global Travelers Vaccine Market, by Type, 2017 (US$ Mn)
2.3. Global Travelers Vaccine Market, by Geography, 2017 (US$ Mn)
Chapter 3. Travelers Vaccine Market: Dynamics and Future Outlook
3.1. Market Overview
3.2. Drivers
3.3. Challenges
3.4. Opportunities
3.5. Attractive Investment Proposition, by Geography, 2017
3.6. Competitive Analysis: Global Travelers Vaccine Market, by Key Players, 2017
Chapter 4. Global Travelers Vaccine Market, by Type
4.1. Overview
4.2. Routine Vaccination
4.2.1. Hepatitis B
4.2.2. Influenza
4.2.3. MMR
4.2.4. Tuberculosis
4.2.5. Others
4.3. Recommended Vaccination
4.3.1. Cholera
4.3.2. Japanese Encephalitis
4.3.3. Diarrhea
4.3.4. Yellow Fever
4.3.5. Others
4.4. Required Vaccination
4.4.1. Malaria
4.4.2. Ebola
4.4.3. Zika
4.4.4. Middle East Respiratory Syndrome
4.4.5. Others
Chapter 5. Global Travelers Vaccine Market, by Geography
5.1. Overview
5.2. North America Travelers Vaccine Market Analysis, 2016 – 2026
5.2.1. North America Travelers Vaccine Market, by Type, 2016 – 2026 (US$ Mn)
5.2.2. North America Travelers Vaccine Market, by Country, 2016 – 2026 (US$ Mn)
5.2.2.1. U.S.
5.2.2.2. Canada
5.3. Europe Travelers Vaccine Market Analysis, 2016 – 2026
5.3.1. Europe Travelers Vaccine Market, by Type, 2016 – 2026 (US$ Mn)
5.3.2. Europe Travelers Vaccine Market, by Country/Region, 2016 – 2026 (US$ Mn)
5.3.2.1. U.K.
5.3.2.2. Germany
5.3.2.3. Rest of Europe
5.4. Asia Pacific Travelers Vaccine Market Analysis, 2016 – 2026
5.4.1. Asia Pacific Travelers Vaccine Market, by Type, 2016 – 2026 (US$ Mn)
5.4.2. Asia Pacific Travelers Vaccine Market, by Country/Region, 2016 – 2026 (US$ Mn)
5.4.2.1. China
5.4.2.2. Japan
5.4.2.3. Rest of Asia Pacific
5.5. Latin America Travelers Vaccine Market Analysis, 2016 – 2026
5.5.1. Latin America Travelers Vaccine Market, by Type, 2016 – 2026 (US$ Mn)
5.5.2. Latin America Travelers Vaccine Market, by Country/Region, 2016 – 2026 (US$ Mn)
5.5.2.1. Brazil
5.5.2.2. Mexico
5.5.2.3. Rest of Latin America
5.6. Middle East and Africa Travelers Vaccine Market Analysis, 2016 – 2026
5.6.1. MEA Travelers Vaccine Market, by Type, 2016 – 2026 (US$ Mn)
5.6.2. MEA Travelers Vaccine Market, by Country/Region, 2016 – 2026 (US$ Mn)
5.6.2.1. GCC
5.6.2.2. Rest of MEA
Chapter 6. Company Profiles
6.1. Baxter AG
6.1.1. Business Description
6.1.2. Financial Information (Subject to data availability)
6.1.3. Type Portfolio
6.1.4. News Coverage
6.2. Bharat Biotech
6.3. GlaxoSmithkline, Plc.
6.4. Inovio Pharmaceuticals, Inc.
6.5. Merck & Co., Inc.
6.6. Novartis AG
6.7. PaxVax Corporation
6.8. Sanofi Pasteur SA
6.9. Valneva SE
6.10. VBI Vaccines, Inc.
FIG. 1 Travelers Vaccine Market: Research Methodology
FIG. 2 Travelers Vaccine: Market Segmentation
FIG. 3 Global Travelers Vaccine Market, by Type, 2017 (US$ Mn)
FIG. 4 Global Travelers Vaccine Market, by Geography, 2017 (US$ Mn)
FIG. 5 Attractive Investment Proposition: by Geography, 2017
FIG. 6 Competitive Analysis: Global Travelers Vaccine Market, by Key Players, 2017
FIG. 7 Global Hepatitis B Travelers Vaccine Market, 2016 – 2026 (US$ Mn)
FIG. 8 Global Influenza Travelers Vaccine Market, 2016 – 2026 (US$ Mn)
FIG. 9 Global MMR Travelers Vaccine Market, 2016 – 2026 (US$ Mn)
FIG. 10 Global Tuberculosis Travelers Vaccine Market, 2016 – 2026 (US$ Mn)
FIG. 11 Global Other Routine Travelers Vaccine Market, 2016 – 2026 (US$ Mn)
FIG. 12 Global Cholera Travelers Vaccine Market, 2016 – 2026 (US$ Mn)
FIG. 13 Global Japanese Encephalitis Travelers Vaccine Market, 2016 – 2026 (US$ Mn)
FIG. 14 Global Diarrhea Travelers Vaccine Market, 2016 – 2026 (US$ Mn)
FIG. 15 Global Yellow Fever Travelers Vaccine Market, 2016 – 2026 (US$ Mn)
FIG. 16 Global Other Recommended Travelers Vaccine Market, 2016 – 2026 (US$ Mn)
FIG. 17 Global Malaria Travelers Vaccine Market, 2016 – 2026 (US$ Mn)
FIG. 18 Global Ebola Travelers Vaccine Market, 2016 – 2026 (US$ Mn)
FIG. 19 Global Zika Travelers Vaccine Market, 2016 – 2026 (US$ Mn)
FIG. 20 Global Middle East Respiratory Syndrome Travelers Vaccine Market, 2016 – 2026 (US$ Mn)
FIG. 21 Global Other Required Travelers Vaccine Market, 2016 – 2026 (US$ Mn)
FIG. 22 U.S. Travelers Vaccine Market, 2016 – 2026 (US$ Mn)
FIG. 23 Canada Travelers Vaccine Market, 2016 – 2026 (US$ Mn)
FIG. 24 U.K. Travelers Vaccine Market, 2016 – 2026 (US$ Mn)
FIG. 25 Germany Travelers Vaccine Market, 2016 – 2026 (US$ Mn)
FIG. 26 Rest of Europe Travelers Vaccine Market, 2016 – 2026 (US$ Mn)
FIG. 27 China Travelers Vaccine Market, 2016 – 2026 (US$ Mn)
FIG. 28 Japan Travelers Vaccine Market, 2016 – 2026 (US$ Mn)
FIG. 29 Rest of Asia Pacific Travelers Vaccine Market, 2016 – 2026 (US$ Mn)
FIG. 30 Brazil Travelers Vaccine Market, 2016 – 2026 (US$ Mn)
FIG. 31 Mexico Travelers Vaccine Market, 2016 – 2026 (US$ Mn)
FIG. 32 Rest of Latin America Travelers Vaccine Market, 2016 – 2026 (US$ Mn)
FIG. 33 GCC Travelers Vaccine Market, 2016 – 2026 (US$ Mn)
FIG. 34 Rest of MEA Travelers Vaccine Market, 2016 – 2026 (US$ Mn)
TABLE 1 Global Travelers Vaccine Market Portraiture
TABLE 2 Global Travelers Vaccine Market, by Type, 2016 – 2026 (US$ Mn)
TABLE 3 Global Routine Travelers Vaccine Market, by Type, 2016 – 2026 (US$ Mn)
TABLE 4 Global Recommended Travelers Vaccine Market, by Type, 2016 – 2026 (US$ Mn)
TABLE 5 Global Required Travelers Vaccine Market, by Type, 2016 – 2026 (US$ Mn)
TABLE 6 Global Travelers Vaccine Market, by Geography, 2016 – 2026 (US$ Mn)
TABLE 7 North America Travelers Vaccine Market, by Type, 2016 – 2026 (US$ Mn)
TABLE 8 North America Travelers Vaccine Market, by Country, 2016 – 2026 (US$ Mn)
TABLE 9 Europe Travelers Vaccine Market, by Type, 2016 – 2026 (US$ Mn)
TABLE 10 Europe Travelers Vaccine Market, by Country/Region, 2016 – 2026 (US$ Mn)
TABLE 11 Asia Pacific Travelers Vaccine Market, by Type, 2016 – 2026 (US$ Mn)
TABLE 12 Asia Pacific Travelers Vaccine Market, by Country/Region, 2016 – 2026 (US$ Mn)
TABLE 13 Latin America Travelers Vaccine Market, by Type, 2016 – 2026 (US$ Mn)
TABLE 14 Latin America Travelers Vaccine Market, by Country/Region, 2016 – 2026 (US$ Mn)
TABLE 15 Middle East and Africa Travelers Vaccine Market, by Type, 2016 – 2026 (US$ Mn)
TABLE 16 Middle East and Africa Travelers Vaccine Market, by Country/Region, 2016 – 2026 (US$ Mn)
TABLE 17 Baxter AG: Company Snapshot (Business Description; Financial Information; Type Portfolio; Key Developments)
TABLE 18 Bharat Biotech: Company Snapshot (Business Description; Financial Information; Type Portfolio; Key Developments)
TABLE 19 GlaxoSmithkline, Plc.: Company Snapshot (Business Description; Financial Information; Type Portfolio; Key Developments)
TABLE 20 Inovio Pharmaceuticals, Inc.: Company Snapshot (Business Description; Financial Information; Type Portfolio; Key Developments)
TABLE 21 Merck & Co., Inc.: Company Snapshot (Business Description; Financial Information; Type Portfolio; Key Developments)
TABLE 22 Novartis AG.: Company Snapshot (Business Description; Financial Information; Type Portfolio; Key Developments)
TABLE 23 PaxVax Corporation: Company Snapshot (Business Description; Financial Information; Type Portfolio; Key Developments)
TABLE 24 Sanofi Pasteur SA: Company Snapshot (Business Description; Financial Information; Type Portfolio; Key Developments)
TABLE 25 Valneva SE: Company Snapshot (Business Description; Financial Information; Type Portfolio; Key Developments)
TABLE 26 VBI Vaccines, Inc.: Company Snapshot (Business Description; Financial Information; Type Portfolio; Key Developments)
